INT112906

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 0
Pain Relevance 0.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Ppp1r1b) nucleus (Ppp1r1b) intracellular (Ppp1r1b)
cytoplasm (Ppp1r1b)
Ppp1r1b (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 5 99.64 Very High Very High Very High
Dopamine 245 98.32 Very High Very High Very High
tetrodotoxin 1 96.40 Very High Very High Very High
opioid receptor 3 95.88 Very High Very High Very High
Glutamate 72 85.20 High High
Opioid 3 82.16 Quite High
nMDA receptor 8 59.00 Quite High
Neuropeptide 1 56.52 Quite High
GABAergic 29 50.00 Quite Low
dopamine receptor 4 30.16 Quite Low
Disease Link Frequency Relevance Heat
Depression 8 5.00 Very Low Very Low Very Low
Targeted Disruption 7 5.00 Very Low Very Low Very Low
Anxiety Disorder 4 5.00 Very Low Very Low Very Low
Generalized Anxiety Disorder 2 5.00 Very Low Very Low Very Low
Stress 2 5.00 Very Low Very Low Very Low
Epilepsy 2 5.00 Very Low Very Low Very Low
Respiratory Failure 1 5.00 Very Low Very Low Very Low
Necrosis 1 5.00 Very Low Very Low Very Low
Adhesions 1 5.00 Very Low Very Low Very Low
Cognitive Disorder 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, DARPP-32 phosphorylation was abolished by both antagonists.
Negative_regulation (abolished) of Phosphorylation (phosphorylation) of DARPP-32 associated with antagonist
1) Confidence 0.55 Published 2010 Journal Addict Biol Section Abstract Doc Link 20456289 Disease Relevance 0 Pain Relevance 0.31
However, neither an NTR1 antagonist, SR48692, an NTR2 antagonist, levocabastine, nor the two combined affected the basal level and the neurotensin-mediated decrease in DARPP-32 Thr75 phosphorylation.
Negative_regulation (decrease) of Phosphorylation (phosphorylation) of DARPP-32 associated with antagonist
2) Confidence 0.33 Published 2003 Journal Eur. J. Neurosci. Section Abstract Doc Link 12956723 Disease Relevance 0 Pain Relevance 0.44
Nonetheless, during transient dopamine inputs alone, the loop acts as a sink, in which binding of PKAc to PP2A or phosphoThr75 actually decreases the amount of free PKAc, and thereby decreases the ability of PKAc to phosphorylate DARPP-32 on Thr34.
Negative_regulation (decreases) of Phosphorylation (phosphorylate) of DARPP-32 associated with dopamine
3) Confidence 0.20 Published 2006 Journal PLoS Computational Biology Section Body Doc Link PMC1562452 Disease Relevance 0 Pain Relevance 0.08
Similarly, if PP2Ac is prevented from dephosphorylating DARPP-32 on Thr75, then instead of an increase in PKAc activation following calcium stimulation, the amount of activated PKAc is decreased (compare Figure 6D).
Negative_regulation (prevented) of Phosphorylation (dephosphorylating) of DARPP-32
4) Confidence 0.18 Published 2006 Journal PLoS Computational Biology Section Body Doc Link PMC1562452 Disease Relevance 0 Pain Relevance 0.03
The resulting cAMP levels influence the activity of PKA that in its activated state catalyzes phosphorylation of DARPP-32, a strong inhibitor of PP-1.
Negative_regulation (inhibitor) of Phosphorylation (phosphorylation) of DARPP-32
5) Confidence 0.05 Published 2008 Journal Frontiers in Molecular Neuroscience Section Body Doc Link PMC2526003 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox